Imedex

Targeted Audience
This e-learning activity is intended for urologists, medical oncologists, radiation oncologists, surgeons, and other healthcare providers involved or interested in management of renal, bladder, and prostate cancer.

Overview
This online activity is the video representation of The US Perspectives in Urologic Oncology meeting that was held in September of this year. This meeting was developed with the endeavor of bridging significant gaps in physician knowledge regarding screening, imaging, diagnosis, prognosis, treatment, and management through surgical strategies and systemic therapies of malignant urologic conditions. The educational format is a combination of didactic sessions and highly interactive case presentations in bladder, renal, and prostate cancer management.

Objectives
After viewing this activity, the participant will be able to:

Describe the newest trends in imaging and use of prognostic markers for renal, bladder, and
prostate cancers
Implement state-of-the-art surgical advancements in renal, bladder, and prostate cancers
Evaluate novel treatment strategies and newly approved agents for renal, bladder, and prostate cancers
Improve case management between the urologist and medical/radiation/surgical oncologist in renal, bladder, and prostate cancers
Apply contemporary chemotherapy strategies for metastatic disease in renal, bladder, and prostate cancers
Identify emerging therapies in a wide variety of urologic cancers

Faculty Disclosure
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex^®, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to
ensure impartiality.

All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

William J. Catalona, MD	Beckman Coulter, Inc.¹
Robert Dreicer, MD, FACP	Bayer Pharmaceuticals¹; Celgene Corporation¹; EMD Pharmaceuticals²; Eli Lilly and Company¹; MERCK & CO., INC.²; Novartis Pharmaceuticals Corporation ²; and sanofi-aventis, U.S.^1,2
Raymond J. Leveillee, MD	LumaSense⁵,Tyco Valley Lab⁵
Michael A. O’Donnell, MD, FACS	Anadys Pharmaceuticals², IDM Pharma Inc.², Eli Lilly and Company^1,2,3 Schering-Plough Corporation^1,2, Viventia Biotech Inc.²
Mack Roach, III, MD	AstraZeneca Pharmaceuticals LP², Siemens⁵, TAP Pharmaceuticals⁵
Arthur I. Sagalowsky, MD	Bioniche Therapeutics²
Gary D. Steinberg, MD, FACS	Vysis, Inc.¹
Daniel P. Petrylak, MD	Eli Lilly and Company² and sanofi-aventis, U.S.^1,2

The following speakers have reported an affiliation with the supporters of this conference:

Daniel P. Petrylak, MD

Bristol-Myers Squibb^1,2

The following speakers do not report any affiliation:

Inderbir S. Gill, MD

Ashish M. Kamat, MD

Charles Ryan, MD

Eric J. Small, MD

Mark S. Soloway, MD

Robert H. Weiss, MD

Laurence H. Klotz, MD

All materials are included with the permission of the authors.

All Imedex staff members who are in a position to control the content of this activity have no financial relationships with any commercial interests that are relevant to this activity.

Faculty

William J. Catalona, MD Northwestern University Chicago, Illinois	Daniel P. Petrylak, MD Columbia University Medical New York, New York
John J. Coen, MD Massachusetts General Hospital Boston, Massachusetts	Mack Roach, III, MD University of California, San Francisco San Francisco, California
Robert Dreicer, MD, FACP Cleveland Clinic Lerner College of Medicine Cleveland, Ohio	Charles Ryan, MD University of California, San Francisco San Francisco, California
Inderbir S. Gill, MD Cleveland Clinic Foundation Cleveland, Ohio	Arthur I. Sagalowsky, MD University of Texas, Southwestern Medical Center of Dallas Dallas, Texas
Ashish M. Kamat, MD M.D. Anderson Cancer Center Houston, Texas	Eric J. Small, MD University of California, San Francisco San Francisco, California
Laurence H. Klotz, MD University of Toronto Toronto, Ontario, Canada	Mark S. Soloway, MD University of Miami School of Medicine Miami, Florida
Raymond J. Leveillee, MD University of Miami School of Medicine Miami, Florida	Gary D. Steinberg, MD, FACS University of Chicago Chicago, Illinois
Michael A. O’Donnell, MD, FACS University of Iowa Iowa City, Iowa	Robert H. Weiss, MD University of California, Davis Davis, California

Sponsorship Statement
This activity is sponsored by Imedex, LLC.

Accreditation Statement
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum of 12.75 AMA PRA Category 1 Credits^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

For questions regarding the accreditation of this activity, please contact

Imedex
4325 Alexander Drive
Alpharetta, GA 30022
Fax: +1(770) 751-7334
Email: enduring@imedex.com

Unapproved and Investigational Uses of Drug and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this activity are the opinions of the authors and do not necessarily reflect the opinions
of Imedex.

Support
The following company has provided an unrestricted educational grant in support of this activity: Bristol-Myers Squibb Company.

Click HERE to view Webcast

System Requirements:

is required for proper viewing. Click here to download

Pentium 500 processor or greater
Windows 98/NT/2000/XP or Mac OS 9/X
Microsoft Internet Explorer 5.5 or later
(Firefox browser currently not supported)
128 MB of RAM
Monitor settings: High color at 800 x 600 pixels
Sound card and speakers

Audio troubleshooting
For general troubleshooting concerning audio or video playback issues consult the following Web link: http://support.microsoft.com/kb/306317.